Clinical and biologic characteristics of the tMDS-AML phase and treatment outcome
| Patient no. . | Latency, mo . | PML/RARα status* . | tMDS phase (mo) . | Karyotype . | tMDS-AML treatment . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 48 | Negative | No | t(10;11)(p14;q21) | MTZ/AraC/VP16 allogeneic SCT | Died of GVHD (day + 50) |
| 2 | 43 | Negative | Yes (+ 18) | Monosomy 7 | Supportive care | Alive in tMDS (at 18 mo) |
| 3 | 46 | Negative | Yes (2) | Failure | Supportive care | Died of disease progression (1 mo) |
| 4 | 48 | Negative | Yes (2) | Del(5q−) | Supportive care | Died of disease |
| (33 from second CR) | progression (5 mo) | |||||
| 5 | 24 | Negative | Yes (5) | 46xx | Allogeneic SCT | Alive in CR |
| (2 from second CR) | (+ 12 mo from SCT) |
| Patient no. . | Latency, mo . | PML/RARα status* . | tMDS phase (mo) . | Karyotype . | tMDS-AML treatment . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 48 | Negative | No | t(10;11)(p14;q21) | MTZ/AraC/VP16 allogeneic SCT | Died of GVHD (day + 50) |
| 2 | 43 | Negative | Yes (+ 18) | Monosomy 7 | Supportive care | Alive in tMDS (at 18 mo) |
| 3 | 46 | Negative | Yes (2) | Failure | Supportive care | Died of disease progression (1 mo) |
| 4 | 48 | Negative | Yes (2) | Del(5q−) | Supportive care | Died of disease |
| (33 from second CR) | progression (5 mo) | |||||
| 5 | 24 | Negative | Yes (5) | 46xx | Allogeneic SCT | Alive in CR |
| (2 from second CR) | (+ 12 mo from SCT) |
By RT-PCR with 10−4 sensitivity.